81 related articles for article (PubMed ID: 8908076)
1. Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation.
Buchler M; Thibault G; al Najjar A; Valentin JF; Guerraoui A; Nivet H; Bardos P; Lebranchu Y
Transplant Proc; 1996 Oct; 28(5):2817-8. PubMed ID: 8908076
[No Abstract] [Full Text] [Related]
2. Flow-cytometry monitoring of antilymphocyte globulin therapy in pediatric renal transplantation.
Brun P; Sterkers G; Maisin A; Benali K; Baudouin V; Macher M; Loirat C
Transplant Proc; 1995 Apr; 27(2):1744-5. PubMed ID: 7725483
[No Abstract] [Full Text] [Related]
3. Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients.
Esposito L; Kamar N; Tkaczuk J; Abbal M; Durand D; Rostaing L
Transplant Proc; 2005 Mar; 37(2):785-7. PubMed ID: 15848531
[TBL] [Abstract][Full Text] [Related]
4. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
Abouna GM; Kumar MS; al-Abdullah IH; Loose J; Sullivan DK; Phillips K; Yost S; Seirka D
Transplant Proc; 1995 Oct; 27(5):2676-8. PubMed ID: 7482872
[No Abstract] [Full Text] [Related]
5. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
6. Clinical immunosuppression, lymphocyte subsets, and host defense mechanisms.
Guttmann RD
Transplant Proc; 1994 Aug; 26(4):1847. PubMed ID: 8066601
[No Abstract] [Full Text] [Related]
7. Sensitive monitoring of polyclonal antilymphocyte agents in renal transplantation.
Clark KR; Taylor RM; Forsythe JL
Clin Transpl; 1993; ():267-74. PubMed ID: 7918160
[TBL] [Abstract][Full Text] [Related]
8. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
9. Flow-cytometric monitoring of ATG therapy for steroid-resistant rejection.
Clark KR; Forsythe JL; Shenton BK; Lennard TW; Proud G; Taylor RM
Transplant Proc; 1992 Feb; 24(1):315. PubMed ID: 1531714
[No Abstract] [Full Text] [Related]
10. Flow cytometric measurements in 104 anti-T-lymphocyte globulin treatments.
Ekberg H; Persson NH; Olsson M; Lundell A; Bredberg A
Transplant Proc; 1992 Dec; 24(6):2551-2. PubMed ID: 1465863
[No Abstract] [Full Text] [Related]
11. The use of thymoglobuline induction in renal transplantation: a pharmacovigilance study.
Hurault de Ligny B; Lebranchu Y
Transplant Proc; 2000 Mar; 32(2):351-2. PubMed ID: 10715435
[No Abstract] [Full Text] [Related]
12. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
[TBL] [Abstract][Full Text] [Related]
13. Inducible IL-2 on CD8 lymphocytes as a postoperative predictor of rejection in renal allograft recipients.
Langley J; Dickerman R; Vergne-Marini P; Williams J; Jensik S; Kenyon N; Anderson J
Transplant Proc; 1993 Feb; 25(1 Pt 2):939-43. PubMed ID: 8442275
[No Abstract] [Full Text] [Related]
14. Asymptomatic cytomegalovirus infection in renal transplants: treatment or no treatment.
Lee PC; Hung CJ; Sung JM; Chang YT; Tsai MT; Dai YS; Liang CC; Lei HY
Transplant Proc; 1996 Jun; 28(3):1513-5. PubMed ID: 8658765
[No Abstract] [Full Text] [Related]
15. The ATG bolus does not induce a persistent inversion of the CD4/8 ratio.
Kaden J; Eichler S; May G; Strobelt V
Transplant Proc; 2002 Sep; 34(6):2379-81. PubMed ID: 12270446
[No Abstract] [Full Text] [Related]
16. Monitoring of ATG therapy by flow cytometry: comparison of one single-platform and two different dual-platform methods.
Reckzeh B; Grebe SO; Rhiele I; Neubauer A; Müller TF
Transplant Proc; 2001 May; 33(3):2234-6. PubMed ID: 11377512
[No Abstract] [Full Text] [Related]
17. The paradox of ATG monitoring in renal transplantation.
Shenton BK; White MD; Bell AE; Clark K; Rigg KM; Forsythe JL; Proud G; Taylor RM
Transplant Proc; 1994 Dec; 26(6):3177-80. PubMed ID: 7998108
[No Abstract] [Full Text] [Related]
18. Improved cadaveric kidney graft survival with initiation of antilymphocyte globulin pretransplant in patients with a positive flow cytometry crossmatch.
Hong JH; Sadeghian M; Sumrani N; Cacciarelli TV; Distant DA; Sommer BG; Norin AJ
Transplant Proc; 1996 Jun; 28(3):1340-1. PubMed ID: 8658685
[No Abstract] [Full Text] [Related]
19. [Low-dose antithymocyte globulins in kidney transplantation: results of a protocol of intermittent administration].
Mourad G; Portales P; Garrigue V; Djamali A; Bouloux C; Chong G; Clot J
Nephrologie; 2000; 21(5):253-8. PubMed ID: 11068775
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of ATG therapy on lymphocyte subsets.
Martins L; Ventura A; Dias L; Henriques A; Sarmento A; Guimarães S
Transplant Proc; 2001 May; 33(3):2186-7. PubMed ID: 11377497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
